Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luigi Naldi

Showing results (1-10 of 289) with videos related to

Pageof 29
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|July 7, 2023
Socioeconomic status, biologics and all-cause mortalityLuigi Naldi
Archives of Dermatology|September 13, 2002
Alefacept for psoriasis: promising drug, open questionsLuigi Naldi
Dermatology (Basel, Switzerland)|October 4, 2007
Health-related quality of life: from health economics to bedside?Luigi Naldi
Clinics in Dermatology|January 20, 2010
Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversiesLuigi Naldi
Acta Dermato-Venereologica|September 8, 2009
Should we use body mass index to predict disease onset and severity in psoriasis?Luigi Naldi
Recenti Progressi in Medicina|November 27, 2014
[Free drug samples for doctors? no, thank you!]Luigi Naldi
Psoriasis (Auckland, N.Z.)|February 2, 2018
Psoriasis and smoking: links and risksLuigi Naldi
Dermatology Reports|September 9, 2021
Top authors in dermatology and beyond: A personal noteLuigi Naldi
Dermatology (Basel, Switzerland)|June 6, 2013
Melanoma management in Italy: learning from practice. A survey from the Intergruppo Italiano MelanomaLuigi Naldi
Dermatology (Basel, Switzerland)|July 30, 2002
The epidemiology of fragrance allergy: questions and needsLuigi Naldi
Pageof 29

Showing results (1-10 of 289) with videos related to

Sort By:
Pageof 29
Journal of the European Academy of Dermatology and Venereology : JEADV|July 7, 2023
Socioeconomic status, biologics and all-cause mortalityLuigi Naldi
Archives of Dermatology|September 13, 2002
Alefacept for psoriasis: promising drug, open questionsLuigi Naldi
Dermatology (Basel, Switzerland)|October 4, 2007
Health-related quality of life: from health economics to bedside?Luigi Naldi
Clinics in Dermatology|January 20, 2010
Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversiesLuigi Naldi
Acta Dermato-Venereologica|September 8, 2009
Should we use body mass index to predict disease onset and severity in psoriasis?Luigi Naldi
Recenti Progressi in Medicina|November 27, 2014
[Free drug samples for doctors? no, thank you!]Luigi Naldi
Psoriasis (Auckland, N.Z.)|February 2, 2018
Psoriasis and smoking: links and risksLuigi Naldi
Dermatology Reports|September 9, 2021
Top authors in dermatology and beyond: A personal noteLuigi Naldi
Dermatology (Basel, Switzerland)|June 6, 2013
Melanoma management in Italy: learning from practice. A survey from the Intergruppo Italiano MelanomaLuigi Naldi
Dermatology (Basel, Switzerland)|July 30, 2002
The epidemiology of fragrance allergy: questions and needsLuigi Naldi
Pageof 29